Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies. (May 2018)

• Record Type: Journal Article
• Authors: Cartin-Ceba, Rodrigo; Halank, Michael; Ghofrani, Hossein-Ardeschir; Humbert, Marc; Mattson, John; Fritsch, Arno; Krowka, Michael
• Is Part Of: Pulmonary circulation. Volume 8:Number 2(2018)
• Publication Date: 2018-05
• Subjects: soluble guanylate cyclase stimulator -- portal hypertension -- pulmonary arterial hypertension; Pulmonary circulation -- Periodicals; Pulmonary circulation; Electronic journals -- Sciences; Periodicals; 616.24005
• DOI: 10.1177/2045894018769305
• Languages: English
• ISSNs: 2045-8932

Abstract

In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open-label extension, PATENT-2.